Partnering CRM for life-science BD

Find the right partnerfor every asset you hold.

Dealase ranks the companies most likely to partner on your asset from their trials, filings, pipelines and past deals, prepares you for every partnering meeting, and keeps every CDA, disclosure and milestone in order after the handshake.

Free for one user · No credit card · US-hosted

Built on public records

ClinicalTrials.gov
SEC EDGAR
NIH RePORTER
PubMed
openFDA
USPTO

The platform

One workspace, six layers. Each does the work a spreadsheet leaves to you.

01 ImportSchedules, attendee lists and spreadsheets, read as they are.

02 MatchEvery company joined to its public record; duplicates merge.

03 EnrichTrials, filings, grants, pipelines and press, each with its source.

04 FitPartners ranked against your assets, with reasons you can check.

05 PipelineDeals by type and stage, with the CDA state on every card.

06 After signingObligations and milestones, watched against public records.

06 After signingObligations and milestones, watched against public records.
05 PipelineDeals by type and stage, with the CDA state on every card.
04 FitPartners ranked against your assets, with reasons you can check.
03 EnrichTrials, filings, grants, pipelines and press, each with its source.
02 MatchEvery company joined to its public record; duplicates merge.
01 ImportSchedules, attendee lists and spreadsheets, read as they are.

01 / Find partners for an asset

See who will license your asset, and why.

Enter an asset once. Dealase ranks companies by how well it fits their trials, pipeline gaps, past deals and ability to pay, with every reason linked to the filing or record behind it.

Fit reasons you can check, not a black-box score
Pipeline gaps and deal history from public filings
Add the best fits to your pipeline in one click

AW-77 · AAV gene therapy · PartnersOut-license · 25 ranked

01
Ostrava Pharma92
3 trials in retinal diseaseIn-licensed an AAV asset (8-K, 2025)No Phase 1 gene therapy
ClinicalTrials.gov · SEC EDGAR · company pipeline page
02
Kinsell Therapeutics84
Ophthalmology franchiseRunway about 9 quartersPartnered at BIO 2026
ClinicalTrials.gov · SEC EDGAR · company pipeline page
03
Merrow Bio71
Capsid platform overlapPhase 2 readout in Q2
ClinicalTrials.gov · SEC EDGAR · company pipeline page

Added to pipelineAW-77 out-license · Ostrava Pharma created at Outreach. The three fit reasons are saved as a note.Open deal Undo

02 / Work a partnering conference

Request the right meetings before the window opens.

Import the attendee list and your schedule. Dealase ranks who is worth requesting, writes a brief for every meeting that says why it matters and what to ask, and turns your notes into follow-ups.

Request list ranked from thousands of attendees
Briefs that cite their sources, ready the night before
A recap for leadership when the event ends

BIO 2027 · Who to requestAttendee list · 18 worth it

94Halvern TherapeuticsBispecifics in your indication Request
88Ravelle PharmaCash to pay an upfront Request
81Sorrel TherapeuticsPhase 2 gap in fibrosis Request
77Gantry BioLicensed a peer asset in 2025 Request
72Tolland TherapeuticsPartnered at BIO-Europe 2026 Request

Brief · Halvern Therapeutics Tomorrow, 10:00 · Room 2BWhy this meetingHLV-3 targets your indication; no Phase 2 asset yet [1]What they wantA second bispecific before their Q3 review [2]What to askAppetite for an option deal; who signs off No CDA yet: share the non-confidential deck only

03 / Run the deal to signature and beyond

Never share a deck without a CDA. Never miss a milestone.

Every CDA, what was shared under it and when it expires sits next to the deal. After signing, Dealase watches your licensee's trials and press releases and flags what may have triggered a payment.

A confidentiality register with expiry alerts
Comparable deal terms when the term sheet arrives
Milestone watch with the evidence attached

Confidentiality register4 CDAs · 1 expiring

Counterparty	Shared	CDA expires
Halvern Therapeutics	Deck, data package	Sep 30, 2027
Quillon Pharma	Deck	Nov 21, 2026
Mirelle Biosciences	None yet	Pending signature
Ravelle Pharma	Deck	Mar 14, 2028

Milestone may be dueYour licensee started Phase 2 for HLV-3. That may trigger the $5M development milestone in section 4.2 of your agreement.ClinicalTrials.gov · Oct 28 Confirm it triggered

04 / How an import works

From schedule to pipeline, in about two minutes.

01 ImportRows from the BIO or partneringONE export are read as they are.
02 MatchEach company is joined to its public record; duplicates merge.
03 TrackEvery meeting lands as a deal at the right stage.

BIO 2027 · schedule.xlsx6 rows

TimeCompanyContactLocationNotes

09:00Corvane BioJ. ParkTable 14asset CVN-214?? confirm

Corvane BioCVN-214 · anti-fibroticPhase 2

09:30Halvern TherapeuticsP. NatarajanRoom 2BCDA sent? check w/ legal

Halvern TherapeuticsHLV-3 · bispecificCDA signed

10:00Asterwood LabsM. OkaforTBDgene tx, preclin

Asterwood LabsAW-77 · gene therapyPreclinical

10:30Mirelle Biosciences—Table 6wants out-license

Mirelle BiosciencesMRL-12 · small moleculePhase 1

11:30Brightfen BiologicsS. ItoTable 22peptide, phase 1b

Brightfen BiologicsBF-2 · peptidePhase 1b

14:00Sabine GenomicsT. LindqvistRoom 3Cdata package req.

Sabine GenomicsPlatform dealResearch

Pipeline · In-license6 deals

Meeting set

Asterwood LabsAW-77 · gene therapyPreclinical

Sabine GenomicsPlatform dealResearch

Met

Corvane BioCVN-214 · anti-fibroticPhase 2

Brightfen BiologicsBF-2 · peptidePhase 1b

CDA

Halvern TherapeuticsHLV-3 · bispecificCDA signed

Mirelle BiosciencesMRL-12 · small moleculePhase 1

Security

Built to pass the questions your IT and legal teams will ask.

US-hostedData stays in the United States, encrypted in transit and at rest.
No patient dataDealase holds companies, business contacts and deals. Health information is rejected.
No LinkedIn scrapingContacts come from what you bring in and from company team pages, nothing else.
Your data trains nothingAI only produces output for you, and every draft waits for your approval.

05 / Pricing